Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Neuroone Medical Technologies Corp

Healthcare US NMTC

0.793USD
0.0045(0.57%)

Last update at 2026-03-10T20:00:00Z

Day Range

0.770.82
LowHigh

52 Week Range

0.852.00
LowHigh

Fundamentals

  • Previous Close 0.79
  • Market Cap27.10M
  • Volume125830
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.33934M
  • Revenue TTM2.82M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM -3.05135M
  • Diluted EPS TTM-0.54

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -11.85949M -9.99961M -9.94817M -13.64016M -6.78116M
Minority interest - - - - -
Net income -11.85949M -9.99961M -9.94817M -13.64016M -6.78116M
Selling general administrative 6.75M 6.71M 6.26M 4.75M 4.28M
Selling and marketing expenses 0.17M 0.27M 0.34M - -
Gross profit 0.46M -0.07079M -0.09775M 0.06M -0.02757M
Reconciled depreciation 0.20M 0.12M 0.08M 0.05M 0.03M
Ebit -11.95525M -10.03077M -9.94709M -4.90226M -5.81339M
Ebitda -11.75598M -9.91215M -9.86634M -4.85465M -5.78582M
Depreciation and amortization 0.20M 0.12M 0.08M 0.05M 0.03M
Non operating income net other - - - - -
Operating income -11.95525M -10.03077M -10.21821M -4.90226M -5.81339M
Other operating expenses 13.91M 10.20M 10.40M 4.90M 5.81M
Interest expense - 0.03M 0.00305M 7.52M 0.28M
Tax provision 0.00000M 0.00000M - - -
Interest income - - - - -
Net interest income - 0.00000M -0.00305M -7.52458M -0.28456M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.19927M -0.03115M 0.27M 7.52M 0.28M
Total revenue 1.95M 0.17M 0.18M 1.93M 0.00000M
Total operating expenses 12.41M 9.96M 10.12M 4.90M 5.81M
Cost of revenue 1.50M 0.24M 0.28M 1.86M 0.03M
Total other income expense net 0.10M 0.03M 0.27M -1.21332M -0.68321M
Discontinued operations - - - - -
Net income from continuing ops -11.85949M -9.99961M -9.94817M -13.64016M -6.78116M
Net income applicable to common shares - -9.99961M -9.94817M -13.64016M -6.78116M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 8.10M 12.82M 7.94M 4.76M 0.53M
Intangible assets - 0.11M 0.13M 0.16M 0.18M
Earning assets - - - - -
Other current assets - 0.30M 0.24M 0.12M 0.04M
Total liab 1.85M 3.22M 1.38M 2.69M 1.77M
Total stockholder equity 6.25M 9.60M 6.55M 2.07M -1.23758M
Deferred long term liab - - - - -
Other current liab - 0.63M 0.53M 0.45M 0.62M
Common stock - 0.02M 0.04M 0.02M 0.01M
Capital stock 0.02M 0.02M 0.04M 0.02M 0.01M
Retained earnings -62.68630M -50.82681M -40.82720M -30.87903M -17.23887M
Other liab - - - - -
Good will - - - - -
Other assets - - 7.79M - -
Cash 5.32M 8.16M 6.90M 4.04M 0.26M
Cash and equivalents - - - - -
Total current liabilities 1.79M 3.10M 1.18M 2.36M 1.77M
Current deferred revenue - 1.46M 0.00862M 0.07M -
Net debt - -7.95743M -6.58567M -2.71701M -0.26075M
Short term debt - 0.08M 0.11M 1.07M -
Short long term debt - - - 1.01M -
Short long term debt total - 0.20M 0.32M 1.32M -
Other stockholder equity - 60.41M 47.35M 32.92M 15.99M
Property plant equipment - 0.53M 0.51M 0.45M 0.05M
Total current assets 7.31M 12.18M 7.29M 4.16M 0.30M
Long term investments - - - - -
Net tangible assets - 9.49M 6.42M 1.91M -1.41642M
Short term investments 0.00000M 2.98M - - -
Net receivables 0.00000M 0.03M 0.05M - -
Long term debt - - - - -
Inventory 1.73M 0.70M 0.10M - -
Accounts payable 0.69M 0.93M 0.53M 0.76M 1.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.00633M
Additional paid in capital - - - - -
Common stock total equity - - - 0.02M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.16M 0.23M
Deferred long term asset charges - - - - -
Non current assets total 0.78M 0.65M 0.65M 0.60M 0.23M
Capital lease obligations 0.06M 0.20M 0.32M 0.31M -
Long term debt total - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments 2.65M -3.24477M -0.06708M -0.12243M -0.12335M
Change to liabilities - 0.52M -0.35031M -0.26960M 0.77M
Total cashflows from investing activities - -3.24477M -0.06708M -0.12243M -0.12335M
Net borrowings - - - 8.36M -0.28300M
Total cash from financing activities 7.40M 12.02M 11.53M 7.32M 5.77M
Change to operating activities - 1.29M -0.01580M -0.15996M -0.87249M
Net income -11.85949M -9.99961M -9.94817M -13.64016M -6.78116M
Change in cash -2.83784M 1.26M 2.86M 3.78M 0.25M
Begin period cash flow 8.16M 6.90M 4.04M 0.26M 0.01M
End period cash flow 5.32M 8.16M 6.90M 4.04M 0.26M
Total cash from operating activities -12.88687M -7.51953M -8.60283M -3.42530M -5.39596M
Issuance of capital stock 8.59M 13.35M 8.83M 0.39M 4.56M
Depreciation 0.20M 0.12M 0.08M 0.05M 0.03M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -1.02215M -0.60625M -0.09829M -0.09829M -0.09829M
Change to account receivables 0.03M 0.02M -0.04834M -0.04834M -0.04834M
Sale purchase of stock -0.11942M - - - -
Other cashflows from financing activities - -1.32730M 2.71M 6.93M 1.73M
Change to netincome - 1.15M 1.77M 8.69M 1.23M
Capital expenditures 0.38M 0.28M 0.07M 0.12M 0.12M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.42851M 1.21M -0.51273M -0.42956M -0.10188M
Stock based compensation 1.11M 0.95M 1.79M 1.84M 0.49M
Other non cash items 0.11M 0.20M -0.01587M 6.74M 0.28M
Free cash flow -13.27099M -7.79476M -8.66990M -3.54773M -5.51931M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NMTC
Neuroone Medical Technologies Corp		 0.0045 0.57% 0.79 - - 10.87 6.93 9.97 -2.1044
ABT
Abbott Laboratories		 -2.1 1.86% 110.55 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -7.27 1.99% 358.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.45 1.59% 89.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.94 2.70% 69.96 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

Neuroone Medical Technologies Corp

7599 Anagram Drive, Eden Prairie, MN, United States, 55344

Key Executives

Name Title Year Born
Mr. David A. Rosa M.D. Pres, CEO & Director 1964
Mr. Ronald W. McClurg Chief Financial Officer 1959
Mr. Steven Mertens Chief Technology Officer 1963
Mr. Mark Christianson Co-Founder, Bus. Devel. Director & Medical Sales Liaison 1967
Mr. Hijaz Haris VP of Marketing NA
Mr. David A. Rosa M.D. President, CEO & Director 1964
Mr. Ronald W. McClurg Chief Financial Officer 1960
Mr. Mark Christianson Co-Founder, Business Development Director & Medical Sales Liaison 1967
Mr. Christopher R. Volker CFA Chief Operating Officer NA
Mr. Hijaz Haris Vice President of Marketing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.